The following data were presented at the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals meeting in Chicago.
• 4SC AG, of Planegg-Martinsried, Germany, presented final results from its Phase IIb COMPONENT study that demonstrated substantial anti-inflammatory activity of vidofludimus in rheumatoid arthritis. The international, multicenter, randomized study evaluated the efficacy of vidofludimus in combination with methotrexate (MTX) compared with MTX alone.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter